Cardiac Surgery Clinical Trial
— MODIFYCSXOfficial title:
Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery Patients: a Phase II Multicenter Trial: A Double-blind, Randomized, Placebo-controlled Trial.
The proposing study is a randomized, double-blind, controlled trial of about 120 patients in 10 centers in Germany. This trial will be started in Germany and recruited mainly at powerful German heart centers only. In this prospective randomized controlled blinded multicenter trial, a total of 120 high-risk cardiac surgery patients will receive either standard of care + OMEGAVEN at 0.20 g/kg ideal body weight (IBW) versus placebo + standard of care.
Status | Recruiting |
Enrollment | 120 |
Est. completion date | December 1, 2025 |
Est. primary completion date | December 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Written informed consent prior to study participation 2. Adult patients (= 18 years) 3. Patients scheduled to undergo elective cardiac surgery with the use of cardiopulmonary bypass (CPB), who are defined as high risk based on having (i) combined valve/coronary artery bypass graft (CABG) or multiple valve surgeries, or combined cardiac/aortic surgical procedures and (ii) one of the following additional risk factors: 1. a high perioperative risk profile, defined as predicted operative mortality of = 8% (European System for Cardiac Operative Risk Evaluation, EuroSCORE II). 2. Age >70 3. Clinical Frailty Score 4 or more 4. Urgent surgery (defined as to be performed within 24-48 hours after admission) 5. Left ventricular ejection fraction <35% Exclusion Criteria: 1. Known hypersensitivity to fish oil (FO)/ fish products or egg protein 2. Pregnancy or lactation period 3. Previous history of atrial fibrillation, atrial flutter and/or atrial tachyarrhythmia 4. Inability or unwillingness of individual to give written informed consent 5. Not expected to survive an additional 48 hours from screening evaluation 6. Lack of commitment to full, aggressive care (anticipated withholding or withdrawing treatments in the first week but isolated "Do not Resuscitate" (DNR) acceptable) 7. Patients admitted with diabetic ketoacidosis or non-ketotic hyperosmolar coma 8. Patients receiving and extracorporeal mechanical assist device (e.g. extracorporal life support systems [ECLS], or intra-aortic ballon pump [IABP]) or for advanced heart failure therapies (e.g. platelet aggregation inhibitors [TAH], ventricular assist devices [VAD]) 9. Enrolment in anyinterventional trial within the last 30 days 10. Already receiving FO-containing medical nutrition products 11. Severe malnutrition (as defined by the BMI<18.5) 12. Severe liver dysfunction defined by Child Pugh Class C. 13. Severe chronic kidney dysfunction defined by the National Kidney Foundation (NKF) stage 4 and 5 by using the glomerular filtration rate (GFR < 30ml/min)1 14. Known severe coagulation disorder |
Country | Name | City | State |
---|---|---|---|
Germany | RWTH Aachen University | Aachen | |
Germany | Charité Universitätsmedizin Berlin | Berlin | |
Germany | University of Bonn | Bonn | |
Germany | Universität Göttingen | Göttingen | |
Germany | University Medical Center Schleswig-Holstein | Kiel | |
Germany | University of Muenster | Münster |
Lead Sponsor | Collaborator |
---|---|
GCP-Service International West GmbH | Charite University, Berlin, Germany, Wuerzburg University Hospital |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Optional-Ultrasound measurement | nested sub-study of skeletal muscle mass | screening, ICU discharge, hospital discharge | |
Other | Optional-Functional Status Score for Intensive Care Unit | Functional Status Score | screening, ICU discharge | |
Other | Optional-Short Physical Performance Battery test | nested sub-study | screening, ICU discharge, hospital discharge | |
Other | Optional-Hand grip dynamometer | nested sub-study | screening, ICU discharge, hospital discharge | |
Other | Optional-Hand held dynamometer | nested sub-study | screening, ICU discharge, hospital discharge | |
Other | Optional-Manual Muscle Testing | nested sub-study | screening, ICU discharge, hospital discharge | |
Other | Optional-Left ventricular ejection function | if available | hospital discharg, 30 days, 3, 6 and 12 months | |
Other | Optional-Markers of inflammation | e.g. procalcitonin [PCT] interleukine-6 [IL-6], white blood cells [WBC] | day 0-7 | |
Other | Optional-Hemodynamics | Adequate hemodynamic support, as defined by stable Cardiac Index (CI), cardiac output (CO), Cardiac Power Index, mean arterial pressure (MAP), central vein pressure (CVP), pulmonary artery diastolic pressure | day 0-7 | |
Other | Sub-study | a serial blood samples and tissue samples( if available from the routine surgical procedure only). | day -1, day 0-7, hopital discharge | |
Primary | Atrial fibrillation | The primary objective is to demonstrate superiority of Omegaven® compared to placebo in the prevention of atrial fibrilation | Until 7 days after surgery | |
Secondary | Weaning from cardiopulmonary bypass (CPB) | Number of attempts to wean from CPB during surgery | During surgery | |
Secondary | Time to discharge alive | time to be alive and discharge from Intensive Care Unit (ICU) | at ICU discharge | |
Secondary | Persistent Organ Dysfunction + Death | requiring supportive technologies during the convalescent phase of critical illness | day 30 | |
Secondary | Days alive and out of hospital | time to be alive and discharge from Hospital | 30 days, 3, 6 and 12 months | |
Secondary | Hospital length of stay | Number of days alive in the ICU/Hosp | at hospital discharge | |
Secondary | ICU length of stay | Number of days alive in the ICU/Hosp | at ICU discharge | |
Secondary | Simplified Acute Physiology Score | Estimates the probability of mortality for ICU patients on admission | day 0-7 | |
Secondary | Therapeutic Intervention Scoring System | a method for measuring workload and calculating costs in the ICU | day 0-7 | |
Secondary | ICU and Hospital Readmission rates | readmission to ICU and hospital | 30 days, 3, 6 and 12 months | |
Secondary | Delta Sequential Organ Failure Assessment Score (SOFA) Score | a scoring system that assesses the performance of several organ systems in the body (neurologic, blood, liver, kidney, and blood pressure/hemodynamics) and assigns a score based on the data obtained in each category. | day 0-7 | |
Secondary | Mechanical ventilation | Duration of mechanical ventilation | day -1-7 | |
Secondary | Stroke | Incidence of stroke | day 0-7 | |
Secondary | Acute Kidney Injury | Kidney Disease: Improving Global Outcomes [KDIGO] stages 1-3 | day 0-7 | |
Secondary | Infections rate | Number of infections | screening, day -1-7 | |
Secondary | Clinical frailty scale | a 9-point scale that quantifies frailty based on function in individual patients | screening, day 30, 3 months | |
Secondary | Development of delirium | assessed by the CAM ICU score | day 0-7, ICU discharge | |
Secondary | Survival status | overall survival | hospital discharge, 30 days, 3, 6 and 12 months | |
Secondary | Physical activity assessment | Katz activities of daily living (ADL) and Lawton's Instrumental ADL (IADL) | screening, 30 days, 3, and 6 months | |
Secondary | Quality of Life (SF-36) | to measure thew quality of life | screening, 30 days, 3, 6, and 12 months | |
Secondary | Adverse Events | possibly related to the investigational product | from day 0 to 12 months | |
Secondary | Postoperative bleeding | bleeding after surgery | day 0-7 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05054179 -
Pecto-Intercostal Fascial Plane Block Catheter Trial for Reduction of Sternal Pain
|
Phase 2/Phase 3 | |
Completed |
NCT04051021 -
Non-Pharmacological Interventions on Patient Experience and Healthcare Utilization in Adult Cardiac Surgery Patients
|
N/A | |
Recruiting |
NCT04604886 -
The Consistency of Cardiac Output Measured by Pulmonary Artery Catheter and LiDCO in Cardiac Surgical Patients
|
N/A | |
Recruiting |
NCT04075981 -
Prevention Atrial Fibrillation by BOTulinum Toxin Injections (BOTAF)
|
Phase 3 | |
Completed |
NCT04062396 -
Comparison of Remowell 2 and Inspire on Delirium and Cognitive Dysfunction
|
N/A | |
Recruiting |
NCT04709705 -
DMSO Cryopreserved Platelets in Cardiopulmonary Bypass Surgery (CRYPTICS)
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05563662 -
SURgical Registry of ENDocarditis EuRope
|
||
Withdrawn |
NCT03289104 -
Improving Sternal Healing After Cardiac Surgery: Sternal Wire vs ZIPFIX
|
N/A | |
Completed |
NCT03563196 -
Diagnosis Of Pulmonary Complications After Cardiac Surgery In Children
|
||
Completed |
NCT02964026 -
Study of Clinical Outcomes Associated With the Pulmonary Artery Catheter (PAC) in Cardiac Surgery Patients
|
N/A | |
Completed |
NCT04199039 -
Effects of Endotracheal Tube Fixation Methods on Hemodynamic Parameters During Endotracheal Suction
|
N/A | |
Completed |
NCT02471001 -
The Levels of Anaesthetics in Heart Muscle During Heart Surgery
|
N/A | |
Completed |
NCT02325726 -
RRI Compared With NephroCheckTM to Predict Acute Renal Failure After Cardiac Surgery.
|
N/A | |
Completed |
NCT01246947 -
Tricuspid Annuloplasty for Moderate Tricuspid Regurgitation Associated With Miral Operation
|
N/A | |
Completed |
NCT01151254 -
Comparison of Propofol Based Versus Volatile Based Anesthesia and Postoperative Sedation
|
N/A | |
Completed |
NCT00821262 -
Sevoflurane in Cardiac Surgery
|
Phase 4 | |
Completed |
NCT00996099 -
Continuous Glucose Monitoring Combined With Computer Algorithm for Intensive Insulin Therapy in Cardiosurgical Patients
|
N/A | |
Completed |
NCT00617955 -
Effects of Aprotinin During Cardiac Surgery/Long Term Death Rates
|
N/A | |
Completed |
NCT00337805 -
Double Blind Randomized Trial of Saline vs Pentaspan for Resuscitation After Cardiac Surgery
|
Phase 2/Phase 3 | |
Completed |
NCT00336466 -
The Erythropoietin NeuroProtective Effect: Assessment in CABG Surgery (TENPEAKS)
|
Phase 2 |